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ABSTRACT
Objective: The objective of the study is to develop optimum, stable, delayed release pellets of omeprazole magnesium (20.6 mg dose). Omeprazole 
magnesium is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ -ATPase at the secretory surface of 
the gastric parietal cell, which is orally administered drug, whereas omeprazole magnesium is degraded in stomach pH, so it is formulated as delayed 
release dosage form to absorb in intestinal pH.
Methods: The formulation of delayed release pellets of omeprazole magnesium was developed by enteric film coating process varying the compositions 
of drug loading, barrier coating, and enteric coating using fluid bed processor. The prepared multiple pellets were filled into hard gelatin capsules as 
a single unit dosage forms.
Results: The dissolution profile of formulation (F8) contains the efficient amount of hydroxypropyl cellulose-L and Eudragit L30 D55 leads to effective 
release of drug in 30 min. Fourier transform infrared and differential scanning colorimeter studies were conducted for the optimized formula to prove 
that the formula was not having incompatibility between the drug and excipients. The scanning electron microscopy studies were conducted to know 
the surface morphology of the pellets.
Conclusion: It was concluded that optimized formulation (F8) shown good similarity with innovator. The results of the accelerated stability of final 
formulation revealed that storage conditions were excellent.
Keywords: Delayed release, Enteric coating, Fluid bed processor, Pellets, Omeprazole magnesium.
INTRODUCTION
Therapeutically, omeprazole, a typical proton pump inhibitor, has an 
irritant effect in the gastric environment and is unstable at the gastric 
pH. To overcome this, enteric coating is required for active content to 
provide its proper therapeutic effect and pharmacological action. The 
proton pump is highly unstable at acidic pH of gastric environment 
and stable at intestine pH ≥5.5, so enteric coated tablets or pellets are 
prepared for the delayed release action [1,2].
Several excellent reviews have provided different types of polymer 
coatings on drugs and use of plasticizers, stabilizers, solubilizers, film 
formers, and different approaches to overcome the stability problems 
and storage conditions. Polymers such as ethyl cellulose, cellulose 
acetate phthalate, hydroxypropyl methylcellulose (HPMC) phthalate, 
and methyl/ethyl acrylic acid copolymers (Eudragit series) were used 
as enteric film coatings for proton pump inhibitors. However, these 
polymers greatly influence the drug stability and bioavailability due to 
the interaction of the free carboxyl groups in enteric polymers and the 
drug. Among the polymers, Eudragit L 30D was the most widely used 
anionic copolymer in pharma industry. It is easily redispersed into 
water with the assistance of small amounts of organic base, resulting in 
redispersed latex at pH 2–3, and ionized at pH ≥5 [3-5]. Low-substituted 
hydroxypropyl cellulose (L-HPC) was used as a binder  and disintegrant 
in the powder layering process on spherical cores and to prepare 
pellets. Due to low particle size and high hydroxypropyl content, it is 
recommended to produce round spheres and rapid dissolution [6].
Chemically, omeprazole magnesium is 5-Methoxy-2-(((4-methoxy-3,5-
dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole magnesium 
salt (2:1) [2]. Omeprazole, an orally administered drug, is a proton pump 
inhibitor that suppresses gastric acid secretion by specific inhibition of the 
H+/K+ ATPase at the secretory surface of the gastric parietal cell [1]. It belongs 
to BCS class II drugs, which has poor solubility and high permeability. The 
dissolution problems of poorly water-soluble drugs have been largely 
solved to improve drug absorption and bioavailability using pelletization 
technique [3]. Pelletization technique is a unique and economical approach 
to overcome drug problems such as poor bioavailability that is related with 
the delivery of hydrophobic drugs, including those that are poorly soluble 
in aqueous as well as organic media [7]. The objective of the present study is 
to formulate and evaluate omeprazole magnesium delayed release pellets 
filled capsules using drug layering technique with fluid bed processor for 
the treatment of acidity and ulcers.
MATERIALS AND METHODS
Materials
Omeprazole magnesium was gift sample from Aurobindo Pharma Ltd., 
(Hyderabad, India). Sugar spheres USNF (250–300 µm) procured from 
JRS Pharma (mfg) and Forum Product Pvt. Ltd. (supp); Hypromellose 
purchased from Signet Chemical Corporation (Mumbai, India); 
Polysorbate 80, HPC-L, Triethyl citrate, Glyceryl monostearate (Imwitor 
900K), Magnesium stearate, and Sodium hydroxide (USNF grades) were 
purchased from Merck Ltd; Methacrylic acid copolymer dis (Eudragit L30 
D55) was purchased from Shin-Etsu Chemical Co., Ltd. (Tokyo, Japan); 
Talc was procured from Luzenac Pharma Ltd. (mfg) and Signet Chemical 




Solubility studies were carried out by preparing saturated solutions 
of omeprazole magnesium in various non-volatile solvents such 
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as methanol, ethanol, acetone, isopropanol, and water and also to 
determine the solubility of drug in the solvents of purified water, pH 6.8, 
and pH 7.4 phosphate buffer. An excessive amount of omeprazole 
magnesium was added in small incremental amounts to a fixed volume 
of the solvent (100 mL of water) with the system and sonicated it for 
24 h at room temperature to ensure complete dissolution of the solute 
in the solvent. The saturated solutions were diluted, filtered, and 
analyzed by UV spectrophotometer (Shimadzu 2800, Japan) at 222 nm.
Drug-excipient compatibility studies
Omeprazole magnesium was mixed with each excipient such as sugar 
spheres, Hypromellose, HPC-L, talc, magnesium stearate, NaOH, 
Eudragit L30 D55, Triethyl citrate, imwitor K90, and polysorbate 80 in 
the ratio (1:0.5), and the mixture was sifted through #40 and taken into 
glass vials. The blends are loaded into stability chamber at 2–8°C and 
40°C/75% RH accelerated conditions for 4 weeks. After the specified 
period, blends are tested for impurity profile and physical change was 
observed to know the compatibility of the drug with excipients in open 
and closed environment.
Formulation of delayed release omeprazole magnesium enteric 
coated pellets
The following steps are involved in manufacturing process of enteric 
coated pellets [8-10,27]. The composition of each formulation and 
process-related parameters are summarized in Tables 1and 2.
Selection of inert core
Sugar spheres are available in different sizes with uniformity. The 
dispensed sugar spheres were sifted through sieve # 50 and # 60, the 
retentions on # 50 were discarded, and fines passed through # 60 were 
selected for further development. Specified quantity of sugar spheres 
was accurately weighed and loaded into fluid bed processor bowl and 
pre-warm with an inlet temperature 45±10°C till bed temperature 
reaches 30±5°C.
Preparation of drug-layered pellets
Specified quantities of hypromellose (HPMC E5) and talc were added 
in 60% and 20% of total required quantity of purified water into 
suitable container with stirrer. Polysorbate 80 was added in 5% of 
water and heated to 60°C under stirring to form a uniform suspension. 
Specified quantity of omeprazole magnesium was added slowly under 
stirring. Sugar spheres were coated with the prepared drug suspension 
using Fluidized Bed processor (Glatt, Mumbai). The weight gain after 
completion of spraying drug loading dispersion was checked, and 
the drug-loaded pellets were dried for not less than 15 min with low 
fluidization at a bed temperature of 35±5°C. The drug-loaded pellets 
were screened through sieve # 40 and # 50, and the retentions on # 40 
and fines passed through # 50 were discarded.
Preparation of subcoating pellets
Talc, magnesium stearate, and HPC-L were added in 60% of total 
required quantity of purified water under stirring into vortex to 
disperse uniformly, and the solution is passed through homogenizer. 
The solution is sprayed onto drug-loaded pellets until target weight of 
pellets was attained. The subcoated pellets were screened through #30 
and #50, and the retentions on #30 and fines passed through #50 were 
discarded.
Preparation of enteric coating pellets
Polysorbate 80 and glyceryl monostearate were added in 20% of total 
required quantity of purified water and heated at 70°C. Talc and triethyl 
citrate were added and stirred for 5 min. The solution is poured into 
homogenizer and allowed to blend for 20 min to make a clear dispersion. 
Eudragit L30 D55 was added. The dispersion was screened through sieve 
#80. The subcoated pellets were loaded into the fluid bed processor bowl 
and the dispersion was sprayed onto the pellets until target weight was 
attained. The enteric coated pellets were screened through #30 and #40, 
and the retentions on #30 and fines passed through #40 were discarded.
Loss on drying (LOD) was noted after each stage of pellet preparation at 
105°C using suitable moister analyzer. LOD should be NMT 5% for drug 
loading and subcoating pellets and NMT 3% w/w for enteric coating 
pellets. Dried pellets were stored in suitable container with double-
lined LDPE triple-laminated aluminum bags with silica gel desiccant 
and characterized its properties. With regard to the final dosage form, 
the multipellets are usually formulated into single-unit dosage forms 




Angle of repose (θ) was assessed to know the flowability of pellets by a 
fixed funnel method, which was essential to the proper scale-up capsule 
filling. Tapped and bulk density of the pellets was determined using 
Tap Density Tester. Two other parameters, compressibility index and 
Hausner’s ratio, were also measured to determine the flowability of the 
pellets and to compare with the prediction made by angle of repose. The 
compressibility index has been used as an indirect measure of moisture 
Table 1: Formulations of omeprazole magnesium (mg/capsule)
Ingredients F1 F2 F3 F4 F5 F6 F7 F8
Core material
Sugar spheres 22.0 22.0 22.0 22.0 22.0 22.0 22.0 22.0
Drug layering (110% w/w build up)
Omeprazole magnesium 20.6 20.6 20.6 20.6 20.6 20.6 20.6 20.6
HPMC E5 premium 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0
NaOH 0.3 0.3 0.3 0.3 0.5 0.5 0.5 0.5
Polysorbate 80 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Talc -- -- -- -- 3.8 3.8 3.8 3.8
Purified water (18% w/w of solids) QS QS QS QS QS  QS QS QS
Subcoating (60% w/w build up)
Hydroxypropyl cellulose 1.0 1.0 1.5 2.0 2.5 3.0 3.5 5.0
Talc 7.0 7.0 7.0 7.0 7.0 7.0 7.0 9.0
Magnesium stearate 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Purified water (12% w/w of solids) QS QS QS QS QS QS QS QS
Enteric coating (80% w/w build up)
Imwitor 900K 0.5 0.5 0.5 0.5 0.5 0.5 0.5 1.0
Polysorbate 80 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.15
Talc 5.0 5.0 5.0 5.0 5.0 5.0 5.0 6.0
Eudragit L30 D55 31.1 31.1 31.1 31.1 31.1 31.1 31.1 40.0
TEC 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0
Purified water (15% w/w solids) QS QS QS QS QS QS QS QS
QS: Quantity sufficient, TEC: Triethyl citrate, HPMC: Hydroxypropyl methylcellulose
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content, bulk density, size, shape, surface area, and cohesiveness of 
pellets. The percentage of compressibility was determined using Carr’s 
compressibility index formula and Hausner’s ratio from the ratio of 
bulk and tapped densities as per USP [11,12].
Fourier transform infrared (FTIR) spectrophotometer
One milligram each of the pure and formulated drug was taken and 
mixed separately with 10 mg of dry powdered potassium bromide. The 
powdered mixture was taken in a diffuse reflectance sampler, and the 
spectrum was recorded by scanning in the wavelength region of 4000–
400/cm using a Jasco FTIR spectrophotometer (Jasco, Essex, UK). The 
IR spectrum of the drug was compared with that of the physical mixture 
to check for any possible drug-excipient interaction.
Differential scanning calorimeter (DSC)
DSC thermograms of the pure and formulated drug were recorded 
on the DSC, Perkin-Elmer Pyris, USA. Samples (2–5 mg) were sealed 
into aluminum pans and scanned at a heating rate of 10°C/min over a 
temperature range of 0–400°C under a nitrogen gas stream.
Scanning electronic microscopy (SEM)
The micrographs of the coated pellets were taken with a scanning 
electron microscopy (Hitachi, Model: S-3400 N, Tokyo, Japan) to study 
the surface morphology of the pellets.
The pellets were mechanically sputtered with gold for 5 min by a 
sputter.
Evaluation parameters of capsules
Evaluation parameters of capsules such as lock length, average 
weight, average weight of net contents, and uniformity of weight were 
determined as per the USP guidelines [11].
Assay
Twenty capsules were accurately weighed, and contents of the capsules 
were transferred into 100 ml volumetric flask. The solution was made 
up with pH 6.8 phosphate buffer and sonicated for 20 min for uniform 
dissolving of the drug. Then, the absorbance value was noted using UV-
VIS spectrophotometer at 222 nm.
Dissolution studies
The dissolution guidelines for omeprazole magnesium containing 
formulations in the monograph of USP35/NF30 [2,11] is for 
delayed release capsules of omeprazole. Therefore, the dissolution 
strategies [9] were adopted for this project, which was studied using the 
DISSO 2000 (Lab India, Mumbai, India), the USP dissolution apparatus 
II (paddle method) at the stirring rate of 100 rpm, and temperature 
maintained at 37±0.5°C. The capsules filled with the coated pellets 
were taken out and placed in 500 mL of 0.1 N HCl with the sinkers 
stirring at 100 rpm for 2 h, and then, the medium was replaced with 
900 mL of phosphate buffer at pH 6.8 to continue the dissolution study 
for another 1 h to examine the in vitro release pattern of the pellets. 
Samples of 5 mL were collected at the intervals of 5, 10, 15, 20, 30, 45, 
and 60 min from each vessel and filtered through a 0.2-μm membrane 
filter into a test tube. The medium in each dissolution vessel was 
replenished after each withdrawal. Samples were then assayed with 
UV spectrophotometer at 222 nm and converted into the cumulative 
amount of omeprazole magnesium release for the time point through 
utilization of the established standard curves in these two media, 0.1N 
HCl and pH 6.8 phosphate buffer. The dissolution experiments were 
conducted in triplicate.
Stability studies
Stability studies were carried out on the optimized formulation, as 
per the ICH guidelines. The capsules filled with coated pellets were 
packed in HDPE bottle and stored at 40°C/75% RH for 6 months as 
per the ICH guidelines. During storage, the samples were monitored 
for appearance. Drug content and dissolution rate of the pellets were 
measured at initial, 1, 3, and 6 months.
RESULTS
Preformulation studies
In preformulation studies, solubility analysis is important because 
the drug has to dissolve in the solvents and also in the dissolution 
medium used. Omeprazole magnesium was found to be freely soluble 
in methanol and ethanol, sparingly soluble in isopropanol and acetone, 
practically insoluble in water. The solubility of omeprazole magnesium 
in different solvents was comparatively represented as purified water 
(0.06 mg/mL) <  pH 7.4 phosphate buffer (0.21 mg/mL) < pH 6.8 
phosphate buffer (0.27 mg/mL). The relative standard deviation for 
the solubility of omeprazole in each solvent was determined to be <5%, 
indicating an accurate assessment.
The results of compatibility studies reveal that the omeprazole 
magnesium was not compatible with the excipients. In physical 
compatibility studies, there was no change in color, odor, and physical 
state of the drug in open environment. Chemical compatibility studies 
were performed to know the compatibility of the drug with excipients 
in open and closed environment. The total % impurity range, initially at 
2–8°C, was 0.03–0.09 and after accelerated conditions at 40°C/75% RH 
was 0.04–0.14. Around 0.01–0.05 drop in potency was observed after 
4 weeks of direct exposure.
Formulation and characterization of enteric coated pellets
Flow properties
The delayed release pellets of omeprazole magnesium were prepared 
using pelletization method. The pellets of different formulations were 
evaluated for bulk and tapped density. The results are shown in Table 3. 
Bulk density for delayed release pellets F1–F8 was found to be between 
0.921 g/cc and 0.948 g/cc. Tapped density for F1–F8 was found to be 
between 0.680 g/cc and 1.006 g/cc. The values obtained were within 
the acceptable range, and there was no large difference noticed. With 
this result, we can calculate the % compressibility of the powder using 
Carr’s compressibility index and Hausner’s ratio. Compressibility index 
was found to be in the range of 12.09–12.84 indicating good flow. 
Hence, all formulations exhibit good compressibility. Hausner’s ratio 
for delayed release pellets was found to be between 1.02 and 1.05. 
With this, the pellets were found to be free flowing. Angle of repose for 
delayed release pellets was found to be between 17.6° and 20.25° which 
was within specified limits of 15–30 and the type of flow was good.
FTIR spectrophotometer
The individual IR spectra of the pure form of omeprazole magnesium 
and formulation of drug with excipients of delayed release pellet are 
shown in Fig. 1. All the characteristic peaks of omeprazole magnesium 
at 3431/cm (N-H, stretching), 3071/cm (Aromatic C-H stretch), 2943 
and 2094/cm (C-H, stretch), 1621/cm (C=C stretch), 1587/cm (C=N, 
stretch), 1510/cm (CH2 bending), 1402/cm (CH Bending), 1157/
cm (C=O Stretch), 1075/cm (C=S Stretch), and 966, 885, and 821/cm 
(C-H Bending) were present in spectra, thus indicating compatibility 
between drug and excipients. It shows that there was no significant 
change in the chemical integrity of the drug.





Inlet temperature (°C) 44–47 50–55 35–45
Product temperature (°C) 20–35 35–45 28–35
Exhaust temperature (°C) 33–36 33–43 25–34
Drive speed (CFM) 25–40 25–35 30–40
Atomization (Barr) 0.8–1.0 0.8–1.8 0.8–3.5
Peristaltic pump speed 2–15 2–15 -
Spray rate (g/min) 2–6 2–8 2–8
Wurster height (cm) - - 2.5–5.0
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DSC
The DSC thermograms of pure drug and layered pellets of omeprazole 
magnesium were conducted to explore the melting activities of drug 
as shown in Fig. 2. DSC analysis showed a sharp endothermic peak 
at 152°C. The melting range of omeprazole magnesium was 150–
155°C as per the United States Pharmacopeia [2]. The formulation of 
omeprazole magnesium in the layered pellets exhibited a shift of the 
endodermic peak to 151.8°C. Hence, the results prove that there was no 
incompatibility between the drug and excipients [18].
SEM
SEM images are taken to evaluate the shape of the pellets and 
dimensions as well. Hence, the shape of the pellets was spherical, 
uniform in appearance, and with slightly rough surface. It is shown in 
Fig. 3.
Evaluation parameters
The lock length of capsules was determined using calibrated Vernier 
calipers, and the length of lock ranges from 14 to 16 mm. Hence, all 
the formulations follow the same range. The average weight, content 
uniformity, and assay of all the formulations were performed, and the 
results are shown in Table 4. The assay of optimum formulation F8 
shows percentage purity up to 99.85% which is underspecified range.
Dissolution studies
The in vitro drug release study was carried out using USP dissolution 
apparatus II (Paddle type), and the dissolution profile of all the delayed 
release formulations, i.e., (F1–F8) is shown in Fig. 4. From the results, 
formulation F1 to F4 showed their release profile up to 69–72% only. It 
is because of the absence of anti-agglomerate agent and low amount of 
disintegrant in drug layering of the formulation. The formulations F5, 
F6, and F7 contain super disintegrant HPC-L which fastens the release 
of drug from the formulations. F5 contains less amount of HPC-L 
when compared to F6 and F7. However, formulations F6 and F7 had 
less weight gain. Formulation F8 shows 100% drug release, which is 
better drug release than the above formulations due to efficient amount 
of eudragit and disintegrant. The dissolution profile of formulation 
F8 was compared with innovator product (Equate), which is shown 
in Fig. 5, and dissolution efficiency (DE) values were calculated as 
per Khan [13]; the DE30 relates to the dissolution of the drug from a 
particular formulation after 30min. DE30 values of formulation F8 and 
innovator were 62.75±0.81 and 64.01±1.02, respectively.
The release profiles of delayed release pellets of omeprazole magnesium 
of all formulations are shown in Table 5. The release kinetics of 
formulations from F1 to F8 follow zero-order drug release because 
the values of regression coefficient obtained for zero-order release 
profiles (r≥0.977) are higher as compared to first-order plots (r≤0.723) 
and Higuchi plots show “r” value in between 0.427 and 0.725. The 
Korsmeyer–Peppas value “r” was found to be between 0.837 and 0.969 
and the n value was found to be >1. The magnitude of the exponent “n” 
indicates the release mechanism of drug. Hence, it follows super case II 
transport in non-Fickian diffusion [14-16].
In dissolution profile comparisons, dissimilarity factor (f1) and 
Table 3: Flow properties of all formulations*
Formulation code Angle of repose (θ) Bulk density (g/cc) Tapped density (g/cc) Hausner’s ratio Carr’s index (%)
F1 29.1±0.23 0.940±0.06 0.989±0.12 1.02±0.23 4.98±0.12
F2 28.5±0.32 0.945±0.065 1.003±0.13 1.01±0.22 4.80±0.12
F3 28.0±0.39 0.948±0.069 1.005±0.15 1.05±0.26 4.78±0.15
F4 27.1±0.42 0.942±0.071 1.006±0.16 1.023±0.22 5.011±0.22
F5 26.8±0.45 0.929±0.075 1.002±0.12 1.03±0.34 4.40±0.25
F6 26.0±0.51 0.929±0.078 0.87±0.13 1.05±0.37 4.28±0.18
F7 25.8±0.59 0.928±0.052 0.68±0.15 1.05±0.39 5.12±0.20
F8 25.1±0.23 0.937±0.055 1.0037±0.16 1.04±0.23 4.11±0.26
Innovator 38.0±0.33 0.406±0.023 0.586±0.013 1.43±0.22 4.11±0.23
*All values are expressed as mean±SE, n=3. SE: Standard error
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similarity factor (f2) were calculated [17,28] to assure performance 
similarity of the two products, and it is important to know how the two 
dissolution curves are close to each other and also to have a measure 
which is sensitive to large differences at any particular time point. 
The comparison of in vitro dissolution profiles of formulation F8 and 
innovator product (Equate) was carried out in pH 6.8 phosphate buffer. 
The values (f1=8.75±1.4 and f2=52.09±1.2) show that there was a 
similarity between both the profiles. The similarity factor fits result 
between 0 and 100. Two drug release profiles are similar if the f2 is ≥50 
and f1 values are ≤15. Therefore, it may be concluded that formulation 
F8 has shown similar drug release characteristic when compared to the 
innovator product (Equate). Hence, it was selected as the optimized 
formulation.
Statistical analysis by independent t-test [14,28] was performed to test 
whether the difference in mean dissolution efficiency values at 30 min 
in pH 6.8 phosphate buffer observed between formulation F8 and 
innovator product was significant or not. The analysis revealed that the 
difference between the methods was statistically significant at p<0.05. 
The absolute value of the calculated t is smaller than critical value 
(2.10<2.77), so the means are not significantly different. Therefore, 
Fig. 3: Scanning electron microscopy image of omeprazole 
magnesium pellets
Fig. 4: Dissolution profiles of all formulations omeprazole 
magnesium pellets in pH 6.8 phosphate buffer
Fig. 5: Dissolution profiles optimum formulation (F8) with 
innovator (equate) in 0.1N HCl and pH 6.8 phosphate buffer
Table 4: Evaluation parameters of capsules
Formulation code Lock length* (mm) Average weight of capsules** (mg) Average weight of net contents** (mg) Assay* (%) 
F1 14.44 ± 0.11 174.8 ± 0.10 136.0 ± 0.02 94.0 ± 0.12
F2 14.45 ± 0.12 175.9 ± 0.12 134.0 ± 0.03 95.0 ± 0.15
F3 14.44 ± 0.13 177.2 ± 0.10 135.0 ± 0.10 95.6 ± 0.23
F4 14.39 ± 0.10 174.0 ± 0.15 136.5 ± 0.11 96.5 ± 0.28
F5 14.44 ± 0.12 175.0 ± 0.13 136.0 ± 0.08 96.6 ± 0.30
F6 14.44 ± 0.11 174.0 ± 0.11 137.1 ± 0.05 97.0 ± 0.23
F7 14.45 ± 0.11 174.9 ± 0.10 137.3 ± 0.06 98.0 ± 0.22
F8 14.45 ± 0.12 174.9 ± 0.11 137.3 ± 0.10 99.5 ± 0.23
*All values are expressed as mean ± SE, n = 5; **All values are expressed as mean ± SE, n = 20. SE: Standard error
there was no difference between formulation F8 and innovator.
Stability studies
Accelerated stability test was conducted for the optimized formulation 
for 6 months at 40°C/75%RH. The results showed that there was no 
change in the formulated pellets during the storage period. The results 
are shown in Table 6.
DISCUSSION
In this study, the delayed release pellets of poorly water-soluble 
omeprazole magnesium were prepared using fluid bed processor 
because the drug showed poor flow property. Saturation solubility of 
omeprazole magnesium was conducted at stomach and small intestine 
pH and observed that relative sink condition (CS/CD) was high at small 
intestine pH. The gastric stability and drug release of uncoated pellets 
were very poor, demonstrating that all of the drugs were degraded 
when pellets were immersed in acid medium for 10 min. Fang et al. are 
observed that the pellets were coated with film-forming agents, and the 
films of coated pellets were excellent without damage in acidic medium 
and had better stability in neutral/alkaline medium and improved oral 
bioavailability of the drug [3,32,33].
Fig. 2: Differential scanning colorimeter thermograms of (a) pure 
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The drug-loaded pellets were coated with hypromellose as a film-
forming agent [20] and HPC-L as a binder or disintegrant in the powder 
layering process on spherical cores to fabricate round spheres and rapid 
dissolution [6,19]. In vitro drug release profiles of all formulations are 
shown in Fig. 4, and from the formulations F1–F4, the absence of talc 
leads to agglomeration of the pellets which led to improper drug release 
and low amount of disintegrant led to less dissolution. Whereas, the 
formulations F5, F6, and F7 contain super disintegrant HPC-L which has 
fasten the release of drug from the formulations. An increased coating 
level led to an amplified extent of diffusion pathways and increasing 
duration of the drug to diffuse through the coating membrane [3].
Eudragit L30 D-55 is the aqueous dispersion of anionic polymers with 
methacrylic acid as a functional group used as enteric film coating for 
drug and significantly influences the drug stability and bioavailability 
due to the interaction of the free carboxyl groups and the drug. It was 
effective and stable enteric coatings with a fast dissolution in the upper 
bowel and easily redispersed into water with the help of small amounts 
of alkali resulting in redispersed latex with pH 2–3. The polymer at 
lower pH and the carboxyl groups are not ionized and render them 
insoluble `[21,22]. At higher pH (≥5), the carboxylic groups became 
ionized, causing polymer to dissolve and specifically drug delivered in 
intestinal site [3-5]. Hence, formulation F8 shows 100% drug release in 
30 min due to efficient amount of Eudragit and disintegrant.
Triethyl citrate (TEC) is a plasticizer strongly affecting the drug release 
from the coated pellets due to the presence of higher hydrophilicity of 
TEC, and the films took up water more rapidly, rendering an increase in 
the permeability of films [23]. When plasticizer is added to the film, it 
provoked greater mobility of the polymer chains by replacing polymer-
polymer interactions by polymer-plasticizer interactions [24]. TEC 
was a better and more compatible plasticizer for Eudragit dispersion 
to render a formation of more uniform and continuous film, hindering 
the leaching out of plasticizer. Thus, the pellets coated by dispersion 
plasticized by TEC were more beneficial to the gastric stability of 
omeprazole magnesium pellets [3].
All formulation results were compared with innovator, and finally, 
F8 formulation is reported as optimum formulation. Based on the 
investigation that the efficient amount of anti-agglomerant (talc) and 
super disintegrant (HPC-L) is the main reason for the release of the 
drug in intestine pH. The calculation of the release kinetics showed 
that the most suitable kinetic model was zero-order, as demonstrated 
in Table 3. As the mechanism of omeprazole magnesium release from 
the delayed release pellets is not well-known, it was calculated using 
the Korsmeyer–Peppas model, which relates drug release exponentially 
to the elapsed time. The model showed that n>1 means that it follows 
super case II transport in non–Fickian diffusion. In super case II 
transport, the rate of solvent diffusion is greater and is the determining 
factor of the diffusion [25,26].
Statistically, independent t-tests were performed, and there was no 
significance difference observed in between optimized formulation 
(F8) and innovator product (Equate) dissolution profile at p<0.05.
FTIR and DSC studies were conducted for optimized formula to prove 
that the formula was not having incompatibility between the drug 
and excipients. A comparison between IR spectra of the pure drug 
and the formulation of drug with the excipients, it was observed that 
all the characteristic peaks of omeprazole magnesium present in the 
combination spectra as well; thus indicating the compatibility of the 
drug with excipients used. In DSC thermograms, the melting activities 
were found to be very close to authentic range of official standard 
[11,18] for both pure and formulated drugs.
The SEM image illustrates the surface morphology of the pellets. The 
ideal pellet shape for the formulation is a spherical form to facilitate 
homogeneous diffusion of an active ingredient and proper pellet coating 
[29]. The prepared pellets were free flowing, white in color, uniform 
in appearance, and with slightly rough surface. The drug content was 
consistent in all formulations.
After storage for 6 months at 40°C/75%RH, the coated pellets 
significantly improved the drug stability [34]. It was attributed to 
the decreased moisture absorption that participated a key role in the 
stability of omeprazole magnesium in optimized formulation [30,31]. 
The enteric polymer Eudragit, due to the presence of an ester structure, 
was liable to hydrolysis in humid conditions, affecting the enteric 
protection in acid medium.
CONCLUSION
The formulations of delayed release pellets of omeprazole magnesium 
were developed by enteric film coating process varying the 
compositions of drug loading, barrier coating, and enteric coating. It 
was prepared by the drug layering technique using fluid bed processor. 
Whereas, omeprazole magnesium was degraded in stomach pH, so it 
was formulated as delayed release dosage form to absorb in intestine 
Table 5: Pearson’s correlation coefficient (r), following linear dissolution data and release exponent (n)*
Formulations Zero order First order Higuchi Korsmeyer–Peppas
r r r r n
F1 0.991 0.723 0.451 0.969 1.186
F2 0.987 0.685 0.499 0.953 1.149
F3 0.988 0.641 0.584 0.926 1.065
F4 0.989 0.640 0.596 0.924 1.091
F5 0.983 0.614 0.662 0.896 1.019
F6 0.983 0.609 0.699 0.890 1.101
F7 0.977 0.570 0.723 0.842 1.079
F8 0.992 0.567 0.723 0.837 1.073
Innovator 0.984 0.598 0.745 0.867 1.117
*All values are expressed as standard mean n = 3
Table 6: Stability studies for formulation F8 at 40°C/75% RH
Storage condition Description Dissolution (%) Moisture Content (%w/w) Assay (%)
Initial Complies 100.00 1.85 99.8
1st month Complies 100.00 1.89 99.5
3rd month Complies 99.99 1.92 99.3
6th month Complies 99.81 1.98 98.5
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pH. The dissolution profile of optimized formulation (F8) contains 
the efficient amount of talc, hydroxypropyl cellulose-L, and Eudragit 
L30 D55 which leads to effective release of drug in 30 min in pH 6.8 
phosphate buffer. FTIR and DSC studies were proved that there was 
no incompatibility between the drug and excipients. The SEM image 
illustrates the surface morphology of the pellets. It was concluded that 
the final formulation (F8) shown good similarity with innovator and 
the results of the accelerated stability studies revealed that storage 
conditions were excellent.
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